ArticleBlood research2020
Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells.
Article in Blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Towards the standardization of human platelet lysate production and its comparison to fetal bovine serum for human hematopoietic cell culture: a scoping review.Frontiers in toxicology · 2025Pooled it
- Exploring ethical, sustainable and effective foetal bovine serum alternatives forFrontiers in toxicology · 2026Review
- Engineering a 3D matrix from porcine plasma for enhanced cell proliferation and differentiation.Frontiers in veterinary science · 2026Article
- Decoding cultured meat manufacturing: a full process model to identify scale-up bottlenecks.Frontiers in nutrition · 2026Article
- The Efficacy of Umbilical Cord (UC) Serum, Human Platelet Lysate, and the Synergistic Effect of Nano-curcumin and Crocin as Supplements in the Proliferation and Survival of Human UC-derived Mesenchymal Stromal Cells (MSCs).Current stem cell research & therapy · 2026Article
- Fibrinogen depletion prevents non-dissociable cell aggregates of feeder-derived NK cell products.Frontiers in immunology · 2026Article
- Application of Human Plasma/Serum to Cell Culture In Vitro: A Translational Research Approach to Better Define Disease Mechanisms.Clinical and translational science · 2025Review
- Article
- Animal origins free products in cell culture media: a new frontier.Cytotechnology · 2025Review
- In vitro regenerative effects of a pooled pathogen-reduced lyophilized human cord blood platelet lysate for wound healing applications.Blood transfusion = Trasfusione del sangue · 2024Article
- High efficiency protocol for platelet derived fibrin gel loaded with mesenchymal stromal cells extracellular vesicles.Regenerative therapy · 2024Article
- Comparison between Platelet Lysate, Platelet Lysate Serum, and Fetal Bovine Serum as Supplements for Cell Culture, Expansion, and Cryopreservation.Biomedicines · 2024Article
- Article
- Message in a Scaffold: Natural Biomaterials for Three-Dimensional (3D) Bioprinting of Human Brain Organoids.Biomolecules · 2022Review
- Article
- Current Methods in the Study of Nanomaterials for Bone Regeneration.Nanomaterials (Basel, Switzerland) · 2022Review
- A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions.International journal of molecular sciences · 2022Article
- Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations.Frontiers in veterinary science · 2022Review
- Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture.Journal of cellular and molecular medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFetal bovine serum (FBS) has been used to support the growth and proliferation of mammalian cells for decades. Owing to several risk factors associated with FBS, several trials have been conducted to evaluate substitutes to FBS with the same efficiency and the lower risk issues.
methodsIn this study, human platelet lysate (HPL) derived from activated human platelets was evaluated as an alternative to FBS due to the associated risk factors. To evaluate the efficiency of the preparation process, platelet count was performed before and after activation. The concentrations of several growth factors and proteins were measured to investigate HPL efficiency. HPL stability was studied at regular intervals, and optimal heparin concentration required to prevent gel formation in various media was determined. The biological activity of HPL and FBS was compared by evaluating the growth performance of Vero and Hep-2 cell lines.
resultsResult of platelet count assay revealed the efficiency of HPL preparation process. Growth factor concentrations in HPL were significantly higher than those in FBS, while the protein content of HPL was lower than that of FBS. Stability study data showed that the prepared HPL was stable for up to 15 months at -20℃. Ideal heparin concentration to be used in different media was dependent on calcium concentration. Results of cell viability assay showed that HPL was superior to FBS in supporting the growth and proliferation of Vero and Hep-2 cells.
conclusionThe HPL prepared by the mechanical activation of platelets may serve as an efficient alternative to FBS in cell culture process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.